Recent Updates
Recently added Catalysts
CMPS Neutral Sentiment

Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026

Key Takeaway: Compass Pathways is set to participate in the RBC Capital Markets Global Healthcare Conference scheduled for May 19-20, 2026. This event will provide a platform for the company to discuss its developments and strategies in the healthcare sector. Further details regarding the presentation or topics to be covered have not been disclosed.
Price reaction · baseline $10.96 (2026-05-13 close) · hit after-hours · clean, no other CMPS news in the window
day 0 close · peak
-3.1%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~27 mo
Minimal dilution risk
Lead asset
Psilocybin
Phase 3 · Major Depressive Disorder

Full Press Release Details

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the RBC Capital Markets Global Healthcare Conference on May 19-20, 2026 and will participate in a fireside chat on May 19 at 10:00am ET.
Management will attend the RBC Capital Markets Global Healthcare Conference on May 19-20, 2026 and will participate in a fireside chat on May 19 at 10:00am ET.
A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

About Compass Pathways

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 synthetic psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).
Compass is headquartered in London, UK, with offices in New York in the US. We envision a world where mental health means not just the absence of illness but the ability to thrive.

Frequently Asked Questions

When is the RBC Capital Markets Conference?

The RBC Capital Markets Global Healthcare Conference is on May 19-20, 2026.

What will Compass Pathways discuss at the conference?

Details on specific topics to be discussed by Compass Pathways have not been disclosed.

Last updated: May 14, 2026